Amplia Therapeutics Ltd (ASX:ATX)'s Dr John Lambert discusses with Proactive its A$12.4 million capital raising. The funds will support a Phase 2 clinical trial of its FAK inhibitor AMP945 in patients with pancreatic cancer. FAK inhibitors are increasingly important in the field of cancer immunology and Amplia has a particular development focus in pancreatic cancer.
Amplia Therapeutics talks A$12.4 million capital raise to support phase 2 clinical trial
